TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17785973
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (SI) of piperacillin/sulbactam (4/1 g every 8 h)
Study: 17785973
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of piperacillin/sulbactam (8/2 g per 24 h after loading dose)
Study: 12589521
Drug: Pindolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (20 mg orally)
Study: 12589521
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of buspirone and pindolol
Study: 12589521
Drug: Buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (30 mg orally) with Pindolol (20 mg orally)
Study: 10783215
Drug: SAK42D 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAK42D 15 mg
Study: 10783215
Drug: SAK42D 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAK42D 30 mg
Study: 10783215
Drug: SAK42D 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAK42D 45 mg
Study: 9816275
Drug: PALA 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA 125 mg/m2
Study: 9816275
Drug: PALA 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA 250 mg/m2
Study: 9816275
Drug: PALA 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA 500 mg/m2
Study: 9816275
Drug: PALA 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA 1000 mg/m2
Study: 9816275
Drug: 5-FU 400
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 400 mg/m2
Study: 9816275
Drug: DP 50
Normalized name: Dextropropoxyphene 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP 50 mg/m2
Study: 9816275
Drug: 5-FU dose
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU dose escalation
Study: 1576631
Drug: clindamycin+gentamicin (C+G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clindamycin+gentamicin (C+G)
Study: 2829267
Drug: ZK 93,426
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZK 93,426 (0.01 mg/kg)
Study: 30475969
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g protein · kg‐1 · d‐1
Study: 30475969
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g protein · kg‐1 · d‐1
Study: 28222641
Drug: Rapid genotyping-guided
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid genotyping-guided treatment (GG)
Study: 26135562
Drug: ivacaftor (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivacaftor (150 mg)
Study: 20394809
Drug: MS-CN (control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-CN (control, no medication, MS provocation)
Study: 20394809
Drug: CN (control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CN (control, no medication, no MS provocation)
Study: 16507196
Drug: prilocaine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prilocaine 1% 40 mL (G1)
Study: 16507196
Drug: prilocaine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prilocaine 1% 30 mL and ropivacaine 0.75% 10 mL (G2)
Study: 16507196
Drug: prilocaine 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prilocaine 1% 20 mL and ropivacaine 0.75% 20 mL (G3)
Study: 16507196
Drug: ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 0.75% 40 mL (G4)
Study: 14645194
Drug: 17beta-E(2) (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-E(2) (4 mg/day) from day 20 until next cycle day 2
Study: 14645194
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no E(2) pre-treatment)
Study: 14645194
Drug: 17beta-E(2) (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-E(2) (4 mg/day)
Study: 8622848
Drug: Holmium:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holmium:YAG laser treatment
Study: 24742939
Drug: Home-based constraint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based constraint induced therapy (CIT)
Study: 18630766
Drug: Bilateral single-site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral single-site thoracic paravertebral block with 25 mL of bupivacaine 0.25% with epinephrine 1:200.000
Study: 18630766
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 mL of 0.9% NaCl)
Study: 11812424
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of water orally administered 30 minutes before verteporfin infusion
Study: 11812424
Drug: No hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hydration before therapy
Study: 1600686
Drug: Verapamil hydrochloride
Normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil hydrochloride extended-release pellet-filled capsule (240 mg) sprinkled on applesauce
Study: 1600686
Drug: Verapamil hydrochloride
Normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil hydrochloride extended-release pellet-filled capsule swallowed intact
Study: 3902237
Drug: ibuprofen-codeine phosphate
Normalized name: codeine / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen-codeine phosphate combination
Study: 27544904
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg monotherapy
Study: 27544904
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg combined with desmopressin
Study: 25377946
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (PAM) short-term treatment (PAM-S) for 2 weeks
Study: 25377946
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (PAM) long-term treatment (PAM-L) for 10 weeks
Study: 25377946
Drug: Pamidronate disodium
Normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate disodium (PAM) treatment
Study: 23525511
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI)
Study: 23525511
Drug: Mometasone furoate/formoterol
Normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI) with a spacer
Study: 1971636
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (ampicillin, gentamicin, metronidazole)
Study: 6993259
Drug: Anti-lymphocytic globulin
Normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-lymphocytic globulin (ALG) 1 g daily for 5 days
Study: 6993259
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with corticosteroids
Study: 28237866
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and bevacizumab (CAP-B) maintenance therapy
Study: 28237866
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and bevacizumab (CAP-B) maintenance therapy in patients with complete or partial response
Study: 21425519
Drug: Preventive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive intervention (watchful waiting, minimally supported CBT-based self-help intervention, problem-solving treatment, referral to a primary care physician for medication if required)
Study: 17289236
Drug: Depot antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot antipsychotics (DA)
Study: 17289236
Drug: Antipsychotic polypharmacy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic polypharmacy (APP), depot antipsychotics (DA), and clozapine
Study: 9770089
Drug: Target Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target Controlled Infusion (Disoprifusor-TCI)
Study: 9770089
Drug: Manually Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually Controlled Infusion
Study: 28693998
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 or 150 mg, given every 2 weeks
Study: 28693998
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 or 150 mg
Study: 26048739
Drug: Stationary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stationary and tablet platforms
Study: 21058940
Drug: Propofol-alfentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-alfentanil combination sedation (group PA)
Study: 15119171
Drug: Needling at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needling at bilateral Neiguan (PC 6) plus oral administration of mexiletine
Study: 15119171
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of mexiletine
Study: 11702162
Drug: Iobitridol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iobitridol (300 mg/ml), 120 ml
Study: 11702162
Drug: Iohexol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iohexol (300 mg/ml), 120 ml
Study: 2500141
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mitomycin C 15 mg/m2 plus DSM 360 mg administered into the hepatic artery (group I)
Study: 2500141
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mitomycin C 15 mg/m2 (group II)
Study: 28224449
Drug: Regadenoson 0.4
Normalized name: REGADENOSON 0.4MG/5ML INJ VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson 0.4 mg during recovery (Ex-Reg)
Study: 28224449
Drug: Regadenoson 0.4
Normalized name: REGADENOSON 0.4MG/5ML INJ VIL 5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regadenoson 0.4 mg 1 hour after inadequate exercise (Regadenoson)
Study: 26195123
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin (100 mg)
Study: 26195123
Drug: Placebo (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.6 g glycerin suppository)
Study: 24299497
Drug: Rivastigmine capsules
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine capsules for 8 months
Study: 24299497
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsules for 8 months
Study: 16545638
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg folic acid daily
Study: 12943949
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg/day) plus Lithium Carbonate (750 mg/day)
Study: 12943949
Drug: Clomipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (150 mg/day) plus Placebo
Study: 10683055
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (100 mg/wk intramuscularly), no exercise
Study: 8151563
Drug: Aminobenzoate potassium
Normalized name: Aminobenzoate Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminobenzoate potassium (KPAB) 12 g/day
Study: 3277606
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc administration
Study: 26270340
Drug: Tacrolimus (TAC)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (TAC) at 0.1 mg/kg/day, target 5‐8 ng/ml
Study: 26270340
Drug: Ciclosporin A
Normalized name: Ciclosporin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin A (CSA) with target 70‐150 ng/ml
Study: 21415807
Drug: Active Individual
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Individual Therapy (Control)
Study: 1489187
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clarithromycin
Study: 1489187
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg clarithromycin
Study: 1489187
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg clarithromycin
Study: 1489187
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clarithromycin
Study: 1489187
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg clarithromycin
Study: 1489187
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg clarithromycin
Study: 3735223
Drug: Cefaclor 125
Normalized name: cefaclor 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 125 mg tds for three days
Study: 3735223
Drug: Cefaclor 125
Normalized name: cefaclor 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 125 mg tds for seven days
Study: 27814258
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser treatment (1 W, 10 Hz for 60 seconds, unfocused at 0.5 cm distance)
Study: 27814258
Drug: GaAlAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAlAs laser treatment (40 mW; 4 J/cm²; 15 seconds per point on 4 points)
Study: 27814258
Drug: 2% neutral
Normalized name: Perfect Choice 2% Neutral Topical Gel (Vanilla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% neutral fluoride gel application (60 seconds)
Study: 24452706
Drug: Robot-assisted arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted arm group therapy (RAGT) + individual arm therapy (IAT) for 30 minutes each, per workday for four weeks.
Study: 24452706
Drug: Individual arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual arm therapy (IAT) for 2x30 minutes, per workday for four weeks.
Study: 24452706
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of treatment with RAGT.
Study: 18425236
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (approximately 30 g)
Study: 18425236
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet plus 10 g of hydrolyzed partially guar-gum
Study: 10582548
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet with one daily fish meal (3.6 g omega3 fatty acids per day)
Study: 8947318
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group in clinical trials of medications for alcoholism treatment
Study: 1880222
Drug: Volmax (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volmax (4 mg) administered after a meal
Study: 1880222
Drug: Proventil Repetabs
Normalized name: Proventil Repetabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proventil Repetabs (4 mg) administered after a meal
Study: 1880222
Drug: Volmax (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volmax (4 mg) administered in fasting state
Study: 1880222
Drug: Proventil Repetabs
Normalized name: Proventil Repetabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proventil Repetabs (4 mg) administered in fasting state
Study: 6852412
Drug: Cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (200 mg orally and intravenously)
Study: 31763269
Drug: Nasal decongestant
Normalized name: Nasal Decongestant
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal decongestant drops
Study: 25644148
Drug: Aprepitant in
Normalized name: aprepitant Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant in combination with conventional 5HT3 blocker-based prophylaxis
Study: 25644148
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (conventional 5HT3 blocker-based prophylaxis only)
Study: 21956278
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy + Basic treatment
Study: 17969890
Drug: Pabing Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pabing Recipe 1 (PR1) plus Madopa tablets
Study: 17969890
Drug: Pabing Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pabing Recipe 3 (PR3) plus Madopa tablets
Study: 17969890
Drug: Fixed Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Chinese recipe plus Madopa tablets
Study: 15889658
Drug: Fuji Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuji Plus with conditioner (10% ferric chloride, 2% citric acid solution)
Study: 2651472
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (25 mg twice daily for 4 days) + PGE2 (1 mg once or twice)
Study: 2651472
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (25 mg twice daily for 4 days) + Placebo
Study: 342679
Drug: Enzyme tablets
Normalized name: Papaya Enzyme Tablets
DrugBank: Ox bile extract (DB14016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme tablets (mutanase and protease)
Study: 21626572
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) immediately
Study: 21626572
Drug: Cognitive processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive processing therapy (CPT) after 10 weeks
Study: 16691031
Drug: Immunotherapy (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (n = 41)
Study: 11781766
Drug: Mixed treatment
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed treatment incorporating both group and individualized treatment
Study: 11781766
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment only
Study: 8509313
Drug: Aspirin (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (320 mg, three tablets every six hours)
Study: 8509313
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and placebo (double-blind administration)
Study: 27119579
Drug: SAR164653 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR164653 (20 to 800 mg single oral doses, repeat doses up to 800 mg)
Study: 27119579
Drug: SAR164653 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR164653 (single dosing)
Study: 27119579
Drug: SAR164653 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR164653 (multiple dosing)
Study: 9002829
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants (subcrestal placement, polished surface sunk by 1 mm)
Study: 9002829
Drug: Test implants
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test implants (subcrestal placement)
Study: 9002829
Drug: Control implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implants (placed at alveolar crest)
Study: 9002829
Drug: Modified gingival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified gingival index at 4 months (test implants)
Study: 1335003
Drug: Treated essential
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated essential hypertensives (propranolol therapy)
Study: 6704507
Drug: Chlorothiazide administered
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorothiazide administered as a solution
Study: 6704507
Drug: Chlorothiazide administered
Normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorothiazide administered as a tablet
Study: 27291387
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with fractional CO2 laser, targeted UVB phototherapy, and topical 0.05% clobetasol propionate cream
Study: 27291387
Drug: Targeted UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted UVB phototherapy and topical 0.05% clobetasol propionate cream
Study: 11983186
Drug: Fluoxetine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (dose stratified from 1.25 mg to 40 mg per day)
Study: 11983186
Drug: Fluoxetine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (dose response)
Study: 1771902
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IgIV) (0.4 g/kg during 5 consecutive days, total dose of 2.0 g/kg)
Study: 1771902
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IgIV)
Study: 31779620
Drug: Implementation outcomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implementation outcomes including pAEs, patient/treatment satisfaction, work satisfaction, safety culture, training-related outcomes.
Study: 29855317
Drug: Life skills
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life skills building education and multiple micronutrient supplementation provided bi-monthly from preconception, twice-weekly during preconception, daily during pregnancy, and daily for 6 months post-partum.
Study: 29855317
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care including non-regulated community-based health sessions and daily iron and folic acid supplementation during pregnancy.
Study: 27237018
Drug: Multiple micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple micronutrient powder (MNP) daily in complementary feeding for 2 months